Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network

Annals of Hematology
Patrizia ZappasodiGiuseppe Rossi

Abstract

Favorable acute myeloid leukemia (AML) patients (pts.) demonstrate a relatively good outcome with standard induction; thus, pts. are generally not addressed to allogeneic transplant in first remission. However, it is not clear if also in a real-life setting, the outcome is homogeneous in the different favorable molecular groups and which are the parameters significantly associated to an increased relapse risk, useful to suggest the need of an intensified approach. In order to clarify this point, we collected clinical data on consecutive unselected AML pts. assigned to favorable category (modified ELN 2010 due to the inclusion of double-mutated CEBPA-positive cases), diagnosed and treated in six centers of the Italian network Rete Ematologica Lombarda (REL) from 2007 to 2015. We assessed response (CR, mCR), relapse rate (CIR), and outcome (OS, DFS) after first-line treatment. A total of 201 pts. was studied and the analysis was performed globally and in each molecular group: t(8;21)(q22;q22)/RUNX1-RUNX1T1 (30 pts., 14.9%), inv. (16)(p13q22) or t(16;16)(p13q22)/CBFB-MIH11 (35 pts., 17.4%), normal karyotype and mutated NPM1 and negative FLT3-ITD (116 pts., 57.7%) or double-mutated CEBPA (CEBPAdm) (20 pts., 10%). Complete remission...Continue Reading

References

Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Liang-In LinHwei-Fang Tien
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea CorbaciogluKonstanze Döhner
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Jan 21, 2016·The New England Journal of Medicine·Adam IveyUNKNOWN UK National Cancer Research Institute AML Working Group
Aug 1, 2012·Leukemia Supplements·R CairoliE Morra

❮ Previous
Next ❯

Citations

Jul 22, 2019·Journal of Clinical Medicine·Antonio Giovanni SolimandoHermann Einsele
Nov 9, 2018·International Journal of Molecular Sciences·Fabio ForghieriMario Luppi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.